| Date | Title | Description |
| 08.07.2021 | Oncopeptides shares updated results from the phase 3 OCEAN study based upon further analysis | BOSTON, July 8, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces updated results and safety... |
| 23.09.2020 | ONCOPEPTIDES AB (PUBL)
Oncopeptides : Interim Report Q2 2020 | I N T E R I M R E P O R T Q2 2020
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of melflufen, a first in c... |
| 18.06.2018 | Industrifonden Life Science recruits Bita Sehat as Investment Manager | Industrifonden strengthens its Life Science investment team through the recruitment of Dr. Bita Sehat as Investment Manager. Bita brings over 10 years of scientific expertise in oncology as well as corporate experience from Europe and North... |
| 22.03.2018 | Oncopeptides has completed a directed share issue of SEK 314 million | Oncopeptides today announces that the company has successfully completed a directed share issue of approximately SEK 314 million (USD 38 million).
> Read the full press release here |
| 22.02.2017 | Oncopeptides AB listed on Nasdaq Stockholm main market | Oncopeptides AB (publ) hereby announces the outcome relating to the offering to acquire shares in the company and the listing on Nasdaq Stockholm. The offering attracted strong interest among Swedish and international investors and the offe... |
| 21.05.2013 | Oncopeptides Completes Series A Financing | Oncopeptides AB, a Stockholm, Sweden-based company working to enhance oncology therapies, completed a Series A financing round.
The amount of the funding was not disclosed.
The round was led by HealthCap, with participation from existing in... |
| - | Oncopeptides has completed a directed share issue of approximately SEK 314 million | Source: Oncopeptides |
| - | Oncopeptides hosts a virtual symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma | Due to the COVID-19 pandemic, the annual hematology meeting will be virtual. Oncopeptides has developed a virtual booth to demonstrate its commitment to the multiple myeloma community, share the comprehensive drug development program and fa... |
| - | Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019 | Overall Conclusions – ANCHOR Poster Presentation
Klaas Bakker, MD, and Chief Medical Officer comments on the ANCHOR data
“The ANCHOR data presented today are truly encouraging and support the future development of melflufen in triplet reg... |
| - | Oncopeptides to Present Promising Phase I/ II Clinical Data at the European Hematology Association in Vienna, Austria, June 11 – 14 2015 | Stockholm, Sweden June 4, 2015
Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – today announced that the clinical results from an ongoing Phase I/II study of safety and efficacy of melflufen... |
| - | New Interim Data in RRMM Patients with Extramedullary Disease from the Pivotal Phase 2 Horizon-study presented at International Myeloma Workshop | The results presented at IMW 2019 by Professor Paul G Richardson in the plenary session “Late Breaking Abstracts” under the title: Activity of Melflufen in RRMM Patients with Extramedullary Disease in the Phase 2 Study (OP-106 HORIZON) – Pr... |
| - | Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today | Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) hereby announces the outcome relating to the offering to acquire shares in the Company (the “Offering”) and the listing on Nasdaq Stockholm. The Offering attracted strong interest amo... |
| - | Program for Oncopeptides Capital Markets Day December 14th, 2018 | Oncopeptides Capital Markets Day Program
8.30 – 09.00 Introduction to Oncopeptides including a Clinical Trials Overview
Jakob Lindberg, CEO of Oncopeptides
9.00 – 09.45 HORIZON and ANCHOR Trials Data Update
Professor Paul G Richardson, ... |
| - | Oncopeptides Annual Report 2019 | The annual report is available as a PDF version on the company’s website below;
www.oncopeptides.com / Investor Relations / Financial reports
For more information, please contact:
Rein Piir, Head of Investor Relations at Oncopeptides
E-... |
| - | New Data Presented from Oncopeptides’ Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress | Stockholm – 16 June 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial. The oral presentation was included in the “Novel strategies in mul... |
| - | Oncopeptides presents new data from phase 2 ANCHOR combination study in multiple myeloma at American Society of Hematology meeting ASH | The primary objective of the phase 2 ANCHOR study is overall response rate, and a secondary objective is progression free survival. The data represents an analysis of both treatment arms, with a cut-off date of October 19, 2020. The overall... |
| - | Oncopeptides strengthens the pre-clinical development and takes over Kancera´s Solna-based laboratory for drug development as of July 1 | “I am very glad that we have gained the opportunity to recruit highly qualified staff and take over laboratory facilities, that meet our needs of cutting-edge expertise in pre-clinical drug development”, says Fredrik Lehmann, EVP Research a... |
| - | Oncopeptides will host a webcast on Monday, January 27th at 11.00 (CET) | Conference call for investors, analysts and the media, Monday, January 27th 2020, at 11 (CET).
Phone numbers for participants from:
Sweden: +46 8 505 58 352
Europe: +44 3333 009 262
USA: +1 833 526 8347
The conference call will also be... |
| - | Oncopeptides provides update regarding COVID-19 impact on the melflufen clinical program | The COVID-19 pandemic is evolving rapidly and will have a significant impact on the global healthcare system. Many hospitals, regions and countries are updating their guidelines and Oncopeptides is taking necessary steps to fully comply wit... |
| - | Oncopeptides to present at the Jefferies London Healthcare Conference on November 14th | Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate melflufen... |
| - | Data from Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting | In the pivotal Phase 2 HORIZON trial for which interim results were presented, melflufen demonstrated promising activity in patients with RRMM, many of whom also have extramedullary disease (EMD). In the study, patients demonstrated an over... |
| - | First patient starts treatment in Oncopeptides’ Phase I / II ANCHOR study with Ygalo® | Ygalo® in clinical development
Ygalo® has been investigated in the treatment of late-stage relapsed refractory multiple myeloma (RRMM) patients. This was done in the clinical study O-12-M1 where strong final results were reported in Decemb... |
| - | Oncopeptides strengthens its organization by appointing Karolina Vilval as General Counsel | For more information, please contact:
Jakob Lindberg, CEO of Oncopeptides
E-mail: *protected email*
Cell phone: +46 70 853 72 92
This information was submitted for publication at 08.00 CET March 2, 2020.
About Oncopeptides
Oncopeptide... |
| - | Oncopeptides reinitiates patient enrollment to the melflufen clinical program following a temporary pause due to the COVID-19 pandemic | The temporary pause did not impact the pivotal phase 2 HORIZON study and the company is on track to submit a file to the FDA based on these data by the end of Q2.
“Relapsed and refractory multiple myeloma is a life-threatening disease with... |
| - | Oncopeptides Presents Encouraging Preliminary Phase I/ II Clinical Data with Melflufen and Dexamethasone for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma at the 56th ASH Annual Meet... | Stockholm, Sweden
Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that initial clinical data from the dose escalation part of a Phase I/II dose escalation/expansion trial is to be presen... |
| - | Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients | Oncopeptides will host a webcast on Tuesday, June 16 at 10.00 (CET) to provide comments on the full top-line results. The webcast can be followed via the link: https://financialhearings.com/event/12977
Summary of results
All data were con... |
| - | Oncopeptides Receives EMA and FDA Orphan Drug Designation for Melflufen in the Treatment of Multiple Myeloma | Stockholm, Sweden March 23, 2015.
Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have both grant... |
| - | Interim data from the ongoing HORIZON trial with melflufen presented in an oral presentation at the 60th American Society of Hematology Meeting | Overall conclusions
The updated phase II data with melflufen in late-stage relapsed-refractory multiple myeloma patients refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitor... |
| - | Oncopeptides to present data from two clinical studies of Ygalo® (melflufen) at American Society of Hematology (ASH), December 9-12 | The abstracts submitted for presentation can be found at www.oncopeptides.se/ Investors & media/Presentations with the following headings:
O-12-M1 – “First report on median overall survival (OS) and improved median progression free sur... |
| - | Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma | “Following the encouraging results of our ANCHOR study this is an important study to further evaluate the potential role of melflufen in triplet regimens”, says Klaas Bakker, MD, PhD, Chief Medical Officer, Oncopeptides AB. “There is an imm... |
| - | Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ) | For further information, please contact:
Jakob Lindberg, CEO of Oncopeptides
E-mail: *protected email*
Telephone: +46 8 615 20 40
Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: *protected email*
Cell phone: +46 70 853 7... |
| - | Oncopeptides AB (publ) announces a listing of its shares on Nasdaq Stockholm | Nasdaq Stockholm has approved the application subject to customary conditions. First day of trading in the Company’s shares is expected to be February 22, 2017. Today the Company publishes a prospectus, the price and other terms of the Offe... |
| - | Interim Report July – September 2018 | Jakob Lindberg, CEO, Oncopeptides
E-mail: *protected email*
Telephone: +46 (0)8 615 20 40
Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: *protected email*
Cell phone: +46 (0)70 853 72 92
Oncopeptides is a pharmaceutical... |
| - | Heavily Pretreated, Relapsed and Relapsed Refractory Multiple Myeloma Patients Showed Significant Clinical Benefit, as Measured by Overall Response Rate and Progression Free Survival, when Treated wit... | Oncopeptides AB, a clinical stage company developing a peptidase targeted therapy – melflufen –
presented clinical results from an ongoing Phase I/II study in patients with relapsed and relapsed
refractory multiple myeloma in combination ... |
| - | Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma | “Patients who receive anti-cancer treatment often get an implanted port, a type of central venous catheter placed under the skin, to limit the number of needle sticks, facilitate intravenous administration and enhance convenience. The PORT ... |
| - | New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting | Overall conclusions from the data presented include:
The data is presented by Professor Paul G. Richardson, MD, RJ Corman Professor of Medicine at Harvard Medical School and Director of Clinical Research at the Jerome Lipper Multiple Myelo... |
| - | Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019 | A wide range of clinical and preclinical data for melflufen in both multiple myeloma and AL amyloidosis will be presented at the ASH annual meeting. Two key data sets that will be presented are;
“The acceptance of six abstracts from our ro... |
| - | Oncopeptides appoints Joseph Horvat as President North America | The appointment of Joseph Horvat as President North America represents a significant milestone in the preparations for a potential US launch of melflufen in late 2020. With more than 23 years of pharmaceutical and biotech industry experienc... |
| - | Oncopeptides will host a webcast on Wednesday, December 9[th] at 14:00 (CET) to provide an update regarding data presented at the ASH annual meeting | At ASH Oncopeptides has presented twelve abstracts, including one oral presentation. Key clinical abstracts focused on new data from the ongoing phase 1/2 ANCHOR combination study and new data from the pivotal phase 2 HORIZON study. The pre... |
| - | Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting | The data offers an analysis of time to next treatment (TTNT) in patients with RRMM who were treated with melflufen and dexamethasone in the Phase 1/2 clinical study named O-12-M1. TTNT is used in Real World Evidence to assist treatment deci... |
| - | Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today | Summary of key results presented
The results show a median progression-free survival (PFS) of 5.7 months, a median overall survival (OS) of 20.7 months and an overall response rate of 31%. The data are very encouraging and compares favorab... |
| - | Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study | The final HORIZON results represent an Overall Response Rate (ORR) improvement for triple-class refractory RRMM patients compared to the interim data presented at the American Society of Hematology (ASH) meeting in December 2019. The HORIZO... |
| - | Anders Martin-Löf has been appointed as the new CFO of Oncopeptides | CFO Birgitta Ståhl has decided to step down as the CFO as the Company expands the organization in Europe and the US, following a successful preparation and execution of Oncopeptides’ IPO. She will continue to work in the Company.
Anders ha... |
| - | Oncopeptides appoints Klaas Bakker as new Chief Medical Officer | Johan Harmenberg has reached retirement age and as the company continues to expand its activities, Johan has decided to step down as CMO but continue to work as a member of the company’s medical team.
From 2015 to present Klaas has worked ... |
| - | New Data Presented at 24th EHA Congress from Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM) | The full posters presented at EHA can be found on the company webpage under:
www.oncopeptides.com / Investors & media / Presentations / 2019 EHA
Comment from CEO Jakob Lindberg
“It is very encouraging to see consistently high respons... |
| - | Oncopeptides announces that two abstracts on multiple myeloma have been accepted by the 2020 ASCO Annual Meeting | Melflufen (melphalan flufenamide) is a first-in-class anticancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. The lead drug candidate is in late stage clinical development for the potential treatment ... |
| - | Patient recruitment in the Pivotal Phase 2-Study HORIZON completed | Oncopeptides is engaged in preparations for submitting a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for accelerated market approval in the United States based on available data from the HORIZON study. The ob... |
| - | Oncopeptides submits a New Drug Application to the FDA for accelerated approval of melflufen in triple-class refractory multiple myeloma patients | Melflufen is the lead candidate coming out of the Oncopeptides’ proprietary PDC-platform. The product is a first-in-class aminopeptidase-targeting peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. The subm... |
| - | Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study | “Today we embarked upon the next phase of our journey with melflufen as we initiated patient enrollment in our phase 1/2 AL amyloidosis study,” says Klaas Bakker, CMO of Oncopeptides. “This study will build upon the promising pre-clinical d... |
| - | Oncopeptides Present Phase 2 Clinical Data at the European Hematology Association in Copenhagen, Denmark, June 2016 | Stockholm, Sweden
Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – announced that clinical results from a Phase 2 study of melflufen and dexamethasone in patients with relapsed-refractory mu... |
| - | Oncopeptides will host a webcast on Tuesday, December 10[th] at 13:00 (CET) to provide an update regarding data presented at the ASH annual meeting | The webcast can be followed via the link:
https://tv.streamfabriken.com/oncopeptides-webcast-post-ash
Participants who would like to ask questions can use the telephone numbers below:
Sweden: + 46 8 56642706
Europe: + 44 3333009270
USA... |
| - | EXTRAORDINARY GENERAL MEETING IN ONCOPEPTIDES AB (PUBL) | Shareholders who wish to participate at the Extraordinary General Meeting must be entered in the share register of the Company, kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation), on Thursday... |
| - | New updated data will be presented from Oncopeptides’ Pivotal Phase 2 HORIZON study in patients with extra medullary disease (EMD) on September 15th | In conjuction with the presentation the new data will be available on the company webpage under:
www.oncopeptides.com / Investors & media / Presentations / 2019 IMW
In the abstract it is reported that out of 121 patients included from... |
| - | Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology | The phase 2 HORIZON data are the basis for the ongoing priority review of the New Drug Application to the US Food and Drug Administration FDA, for accelerated approval of melflufen in combination with dexamethasone in triple-class refractor... |
| - | Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today | CEO comments on HORIZON
“In the HORIZON trial, we are studying Ygalo® in patients that are advanced in their myeloma disease with very poor prognosis and no established treatment options. These patients are suffering from disease progressi... |
| - | Oncopeptides announces new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting | Melflufen (melphalan flufenamide) is a first-in-class anticancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in late stage clinical development for a potential treatment of patients with... |